Rising Cost Effectiveness Considerations Isha Bangia PhamD MBA Ulrich Neumann FRSA, MBA, MSC MA We would like to acknowledge the research of Maximilian Vargas, PhD MBA. Email: eva-bd@certara.com Figure 1. Payer readiness to employ ICER in P&T• The public debate around drug pricing has spurred demand for standardized value assessment in the US. A venture-funded think-tank called “ICER” (Institute for Clinical and Economic Review), has made its name as America’s “drug price watchdog”, selecting pharmaceutical products for review under cost effectiveness criteria. The incremental health gains are measured in quality adjusted life years and equal value of life years gained, as complimentary method the organization suggests for life extending treatments (Figure 2). • 97% of repor

Join for free to read